Pure Marrow

Executive Summary

Pure Marrow, Inc. is a stealth-mode biotechnology company pioneering a novel bedside stem cell therapy platform. Unlike conventional approaches that require ex vivo culture or genetic manipulation, Pure Marrow's technology enables the harvesting and isolation of clinically relevant stem cell doses directly at the patient's bedside. This innovative method aims to simplify and accelerate stem cell delivery, potentially reducing costs and improving patient access. Founded in 2020 and based in San Francisco, the company is privately held and has not disclosed funding or valuation. While still in early development, Pure Marrow's approach addresses key limitations in cell therapy by eliminating complex lab-based processing, which could offer significant advantages in scalability and clinical adoption. However, the company remains in stealth mode, so limited public information is available. The potential impact of its platform on hematology and cell therapy fields is substantial, but execution risks and a lack of clinical data temper near-term expectations.

Upcoming Catalysts (preview)

• Q2 2027First preclinical or clinical data readout40% success
• Q4 2026Strategic partnership or licensing agreement25% success
• Q3 2026Series A or B financing round announcement60% success